Becton Dickinson Earns EUA for COVID-19/Flu Combo Antigen Test
The FDA has granted Emergency Use Authorization for Becton Dickinson’s (BD) BD Veritor test for rapid detection of SARS-CoV-2 and the flu.
The test is run on the company’s BD Veritor Plus System and distinguishes between SarS-CoV-2, influenza A and influenza B, taking approximately 15 minutes to deliver positive or negative results for all three viruses.
BD intends to launch the test this summer in time for the upcoming flu season. The test is intended for patients suspected of having COVID-19, influenza A or influenza B within six days of the first symptoms appearing.